A quick peek into the report
Asia-Pacific MRD Testing Market
Analysis and Forecast, 2023-2033
Frequently Asked Questions
Companies manufacturing and distributing different test, assays and panels used for MRD testing in leukemia, lymphoma, and solid tumors, as well as startups looking to enter the MRD market, should buy this report.
The global MRD testing market is projected to reach $6.67 billion by 2033 from $1.47 billion in 2022, growing at a CAGR of 14.81% during the forecast period 2023-2033.
MRD (Minimal Residual Disease) tests are medical assessments used to detect and measure the presence of residual cancer cells in a patient's body after treatment. These tests are crucial in evaluating the effectiveness of cancer treatments and determining the risk of disease recurrence. They help guide further treatment decisions and monitor a patient's progress.
MRD testing detects cancer cells at a molecular or cellular level, whereas traditional screening methods like imaging or biopsy primarily focus on identifying tumors or abnormal growths. MRD testing provides more precise information about disease progression and treatment response, often at earlier stages.
MRD testing is frequently employed in hematological cancers such as leukemia, lymphoma, and multiple myeloma. However, it is increasingly being utilized in the assessment of solid tumors, including breast cancer, lung cancer, colorectal cancer, and others, as research continues to validate its utility across various cancer types.